Close Menu

NEW YORK (GenomeWeb) – With evidence building that monitoring a tumor's mutational landscape can be done by evaluating circulating tumor DNA or circulating tumor cells, companies are increasingly looking to move into the liquid biopsy market.

Over the last several years, researchers have published a number of studies demonstrating that next-generation sequencing of ctDNA or CTCs can give a representative picture of a patient's tumor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Moderna says it would be able to quickly update its SARS-CoV-2 vaccine to address new genetic variants if needed, MIT's Technology Review reports.

Johnson & Johnson reports interim results from a Phase 1/2 study of its SARS-CoV-2 vaccine in the New England Journal of Medicine, according to Bloomberg.

Investigators from the World Health Organization have arrived in China to look into the origins of SARS-CoV-2, NPR reports.

In Nature this week: a new method for high-throughput amplicon sequencing, and more.

Feb
11
Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
17
Sponsored by
BioLegend

Host immune responses play a central role in controlling SARS-CoV-2 infection, but they remain incompletely characterized and understood.

Feb
18
Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before.